Can pneumococcal meningitis surveillance be used to assess the impact of pneumococcal conjugate vaccine on total invasive pneumococcal disease? A case-study from South Africa, 2005-2016.
Female
Heptavalent Pneumococcal Conjugate Vaccine
/ immunology
History, 21st Century
Humans
Incidence
Male
Meningitis, Pneumococcal
/ epidemiology
Pneumococcal Vaccines
/ immunology
Public Health Surveillance
Serogroup
South Africa
/ epidemiology
Streptococcus pneumoniae
/ classification
Vaccines, Conjugate
/ immunology
Conjugate vaccine
Invasive disease
Meningitis
Streptococcus pneumoniae
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
10 09 2019
10 09 2019
Historique:
received:
04
09
2018
revised:
17
04
2019
accepted:
29
04
2019
pubmed:
12
5
2019
medline:
26
9
2020
entrez:
12
5
2019
Statut:
ppublish
Résumé
South Africa introduced seven-valent pneumococcal conjugate vaccine (PCV7) in 2009 and PCV13 in 2011. We aimed to compare the estimated impact of PCV on pneumococcal meningitis (PM) to impact of PCV on total invasive pneumococcal disease (tIPD) based on risk reduction after PCV introduction. We conducted national, laboratory-based surveillance for tIPD during 2005-2016. We estimated and compared rates of PCV13 and non-PCV13 serotype disease among tIPD and PM in individuals aged <5 years and ≥5 years, and compared these rates between the 2005-2008 pre-PCV introduction period and two time points after PCV introduction, 2012 and 2016. We enrolled 45,853 tIPD cases; 17,251 (38%) were PM. By 2016, IPD caused by all serotypes decreased 55% (95%CI -57% to -53%) for tIPD, and 54% for PM (95%CI -58% to -51%), 0.7% difference between estimates (p = 0.7). No significant differences were observed between PCV7-serotype disease reduction in tIPD and PM in both age groups or the additional 6 serotypes included in PCV13 in <5 year olds in 2012 and 2016. In 2012 there was a significant difference between increases in non-PCV13 serotype disease in those ≥5 years for tIPD and PM (32% greater increase in PM, p < 0.001), but this difference was absent by 2016. There was a significant difference between the estimated decrease in additional PCV13 type disease in 2016 between tIPD and PM for those aged ≥5 years (28% greater reduction in PM, p = 0.008). PM showed similar reductions to tIPD seven years after PCV introduction in vaccine serotype disease in those <5 years, and increases in non-vaccine serotype disease in all ages.
Identifiants
pubmed: 31076159
pii: S0264-410X(19)30590-0
doi: 10.1016/j.vaccine.2019.04.090
pmc: PMC7804388
mid: NIHMS1659069
pii:
doi:
Substances chimiques
Heptavalent Pneumococcal Conjugate Vaccine
0
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Historical Article
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
5724-5730Subventions
Organisme : NCIRD CDC HHS
ID : U51 IP000528
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
BMC Med. 2016 Dec 21;14(1):211
pubmed: 27998266
MMWR Morb Mortal Wkly Rep. 2009 May 15;58(18):493-7
pubmed: 19444153
MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1159-62
pubmed: 25503919
PLoS One. 2016 Feb 10;11(2):e0149104
pubmed: 26863135
Vaccine. 2016 Aug 31;34(38):4543-4550
pubmed: 27475471
S Afr Med J. 2011 Jul 28;101(8 Pt 2):579-82
pubmed: 21920136
Wkly Epidemiol Rec. 2012 Apr 6;87(14):129-44
pubmed: 24340399
Vaccine. 2013 Aug 28;31(38):4200-8
pubmed: 23684826
Health Policy Plan. 2010 May;25(3):171-85
pubmed: 19955092
N Engl J Med. 2014 Nov 13;371(20):1889-99
pubmed: 25386897